SARMS LGD-4033 500mcg x 32 Capsules
SARMS LGD-4033 500mcg x 32 CapsulesPotency: 500mcg Caps
Delivered As: 500mcg Capsules x 32 Capsules
Transdermal Option: 400mcg/mL x 30mL – Apply 1mL daily for 30 days
Oral Option: 500mcg capsules x 32 capsules – Take ONE capsule daily for 32 consecutive days
Description-Selective Androgen Receptor Modulators (SARMs) provide the benefits of traditional anabolic/androgenic steroids such as testosterone (including increased muscle mass, fat loss, and bone density), while having a lower tendency to produce the unwanted side e ects of steroids (aromatization / increased DHT). By acting/stimulating on the androgen receptor, SARMs can provide a similar therapeutic outcome to androgen therapy without any increase in androgen levels. SARMs have the potential to take the place of the androgens, and therefore exert many of the same positive effects on muscle tissue as anabolic steroids like testosterone. SARMs can be administered in an injectable dosage form and are absorbed orally, but are not liver toxic like most oral steroids are. The anabolic effect has been measured to be roughly the same or greater than testosterone. It has also been shown to produce dose-dependent increases in bone mineral density and mechanical strength in addition to being able decrease body fat and increase lean body mass. LGD-4033 is a relatively new SARM on the market. It can be dosed orally at low doses and has a very strong anabolic effect.
Clinical Research-The Safety, Pharmacokinetics, and E ects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor Modulator, in Healthy Young Men Shehzad Basaria , Lauren Collins , E. Lichar Dillon, Katie Orwoll , Thomas W. Storer, Renee Miciek , Jagadish Ulloor , Anqi Zhang , Richard Eder , Heather Zientek , Gilad Gordon, Syed Kazmi , Melinda She eld-Moore , and Shalender Bhasin. Background: Concerns about potential adverse e ects of testosterone on the prostate have motivated the development of selective androgen receptor modulators that display tissue-selective activation of androgenic signaling. LGD-4033, a novel nonsteroidal, oral selective androgen receptor modulator, binds androgen receptor with high a nity and selectivity. Objectives: To evaluate the safety, tolerability, pharmacokinetics, and effects of ascending doses of LGD-4033 administered daily for 21 days on lean body mass, muscle strength, stair-climbing power, and sex hormones. Methods: In this placebo-controlled study, 76 healthy men (21 – 50 years) were randomized to placebo or 0.1, 0.3, or 1.0 mg LGD-4033 daily for 21 days. Blood counts, chemistries, lipids, prostate-specific antigen, electrocardiogram, hormones, lean and fat mass, and muscle strength were measured during and for 5 weeks after intervention. Conclusions: LGD-4033 was safe, had favorable pharmacokinetic profile, and increased lean body mass even during this short period without change in prostate-specific antigen. Longer randomized trials should evaluate its efficacy in improving physical function and health outcomes in select populations.
ProtocolTransdermal Option: 400mcg/mL x 30mL – Apply 1mL daily for 30 days Oral Option: 500mcg capsules x 32 capsules – Take ONE capsule daily for 32 consecutive days Please note, as this is a prescription item, one of our doctors will review your profile and approve your order if appropriate. A prescription will only be issued in accordance to the prescribing guidelines, and for use that strictly complies to the doctor’s directions and dosage. This script will be forwarded to our dispensary team, and placed in our secure, internal records.